Related Experiment Video
Updated: Apr 17, 2026

Humanized NOD/SCID/IL2rγnull (hu-NSG) Mouse Model for HIV Replication and Latency Studies
Published on: January 7, 2019
Treatment optimization of naïve HCV-1 patients using IL28B, RVR and fibrosis stage
Lucio Boglione1, Jessica Cusato1, Giuseppe Cariti1
1Unit of Infectious Diseases, University of Turin, Department of Medical Sciences, Amedeo di Savoia Hospital, Turin, Italy.
Abstract:
The treatment of patients with HCV genotype 1 is quickly changing. The clinician could optimize the selection of patients who may benefit from standard therapy with pegylated-interferon and ribavirin instead of more expensive new combinations with the directly acting antivirals. We retrospectively examined in our cohort of 232 patients with genotype 1 infection the role of interleukin 28B (both rs8099917 and rs12979860), fibrosis stage and rapid virological response. Global SVR in TT/CC patients was 88.3% (98% in F0-F1, 80% in F2-F3); in TT/TC was 68.2 (85% in F0-F1, 71.4% in F2-F3). Rapid virological response was related to rs12979860 CC genotype but is not useful to predict the virological response in TG/GG patients at rs8099917. The standard dual therapy may be successfully administered in all TT/CC and TT/TC patients without F4 fibrosis score. Conversely, patients with TG/CC or GG/CC genotypes should be treated with other therapeutic options.
Related Concept Videos
Inhibitors of Viral Protein Synthesis
Retrovirus Life Cycles
Cirrhosis II: Pathophysiology
Chronic Pancreatitis II: Collaborative Care
Assessment:
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
Viral Hepatitis I: Introduction

